APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sarah L SammonsKira RaskinaNatalie DanzigerLaura AlderAlexa B SchrockJeffrey M VenstromKeith L KnutsonE Aubrey ThompsonKim McGregorEthan S SokolSaranya ChumsriPublished in: JCO precision oncology (2022)
APOBEC+ HR+ HER2- patients had shorter TTD on first-line ET plus CDK4/6i relative to APOBEC- patients. Further research is needed to optimize the treatment of APOBEC+ HR+ HER2- BC and to investigate the efficacy of immunotherapeutic strategies in this population.
Keyphrases
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- endothelial cells
- peritoneal dialysis
- tyrosine kinase
- type diabetes
- young adults
- dna methylation
- skeletal muscle
- metabolic syndrome
- mesenchymal stem cells
- cell proliferation
- replacement therapy
- weight loss